ProPhase Labs to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
ProPhase Labs (Nasdaq: PRPH) announced that CEO Ted Karkus will present a corporate overview during the Access to Giving Virtual Investor Conference from July 13-15, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ProPhase Labs (Nasdaq: PRPH) announced that CEO Ted Karkus will present a corporate overview during the Access to Giving Virtual Investor Conference from July 13-15, 2021. Karkus's presentation is scheduled for July 15 at 9:30 AM ET, with management available for one-on-one meetings throughout the event. ProPhase Labs specializes in medical science and technology, including diagnostic testing for COVID-19 and other respiratory illnesses, with results provided in under 24 hours. For more details, visit www.ProPhaseLabs.com.
Details
News Market Reaction – PRPH
The recorded move for PRPH in the trading session of this news was +4.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, NY, July 12, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announced that Chief Executive Officer Ted Karkus will present a corporate overview at the Access to Giving Virtual Investor Conference being held on July 13 - 15, 2021.
Mr. Karkus will deliver his corporate presentation on July 15 at 9:30am ET. Management will be available for one-on-one meetings to be held throughout the conference.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com.
Investors can register here.
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) is a diversified medical science and technology company. The Company’s subsidiary, ProPhase Diagnostics, offers a broad array of clinical diagnostic insights and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients with SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Our methodology also has the capability to identify the possibility of mutations. Critical to COVID testing, results are provided in under 24 hours. ProPhase also offers PCR (polymerase chain reaction) testing for Influenzas A and B and RSV. ProPhase Diagnostics now offers antigen and antibody/immunity tests in partnership with scientists to broaden its COVID-19 testing beyond RT-PCR testing. ProPhase Labs researches, develops, manufactures, distributes, markets, and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.
Contact:
CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.